Spinal Fusion and Bone Healing Enhancement Products (for New Mexico Only)
State-specific UnitedHealthcare medical policy (New Mexico) governing medical necessity and coverage determinations for spinal fusion grafts and bone-healing enhancement products used in spinal fusion procedures.
Policy Summary
PayerUnitedHealthcare
PolicySpinal Fusion and Bone Healing Enhancement Products (for New Mexico Only)
Policy CodePolicy CS009NM.C
Change TypeCoverage clarification and operational updates
Effective DateDecember 1, 2025
Next Review DateN/A
Key ActionEnsure medical records fully document medical necessity (history, physical exam, diagnostic tests) and include rationale and informed-consent details when requesting coverage for osteobiologic or fusion products.
Added language to clarify Ceramic-Based Products [e.g., beta tricalcium phosphate (b-TCP), calcium phosphate, calcium sulfate] used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary.
Added language describing medical records documentation requirements to support medical necessity determinations.
Added definitions for Osseointegration, Osteoconduction, and Osteoinduction; updated definitions for Allograft, Autograft, and Bone Marrow Aspiration.
Removed reference link(s) to a Medical Policy titled: Interspinous Fusion and Decompression Devices (for New Mexico Only) and Spinal Fusion and Decompression (for New Mexico Only).
Updated Clinical Evidence and References sections to reflect the most current information.
State-specificApplies only to
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
1700Expandable vs static cages meta-analysis sample
Medically Necessary and Not Medically Necessary Products
Proven and medically necessary products
The following products are considered proven and medically necessary for enhancement of spinal fusion when used appropriately:
ANY of the following
Autografts (including Bone Marrow Aspirate used for bone grafting)
Demineralized Bone Matrix (DBM) without added products listed as unproven and not medically necessary
Allograft-based products not listed below as unproven and not medically necessary
InFUSE Bone Graft (rhBMP-2) — lumbar spine
Approach is anterior or oblique and used in conjunction with an FDA-approved interbody fusion device
Skeletally mature individual (>= 18 years of age or radiographic evidence of epiphyseal closure)
Diagnosis: degenerative disc disease (DDD)
Fusion involves vertebral bodies L2-S1
Spondylolisthesis at involved level no more than grade 1 (<= 25% displacement)<= grade 1 (25% displacement)
Single-level fusion only
InFUSE/MASTERGRAFT Posterolateral Revision Device System
Implanted via a posterolateral approach
Presence of symptomatic posterolateral lumbar spine pseudoarthrosis
Skeletally mature patient (older than 21 years of age or radiographic evidence of epiphyseal closure)
Autologous bone and/or bone marrow harvest is not feasible or is not expected to promote fusion
Unproven and not medically necessary products
The following products are considered unproven and not medically necessary for enhancement of spinal fusion and bone healing due to insufficient evidence:
Human amniotic tissue materials, including amniotic fluid stem cell substitutes
Recombinant human bone morphogenetic protein-2 (rhBMP-2, e.g., InFUSE) and InFUSE/MASTERGRAFT for indications not included in the proven list above
Ceramic-based products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components including Bone Marrow Aspirate (BMA)
Summary of clinical conclusions in this document section
Extracted conclusions and coverage-relevant determinations from the evidence reviewed in this part:
ANY of the following
rhBMP-2 (recombinant human BMP-2): Evidence shows more rapid and/or higher likelihood of radiographic fusion compared with autograft for lumbar fusion; clinical improvements in pain/disability/QOL are inconsistent and short-term safety appears reasonable, but there is limited long-term safety data (potential low cancer risk) and specific off-label uses have documented higher complication rates (notably cervical).
Ceramic-based products: Multiple RCTs and intra-patient noninferiority trials report noninferiority or equivalence of certain biphasic calcium phosphate and other ceramic products versus autograft for posterolateral and interbody fusion in selected settings; results are mixed and limitations include small sample sizes, intra-patient design, heterogeneity of products and procedures, and limited long-term outcomes.
Bioactive glass: Evidence is limited and very low quality; some case series and small studies report promising fusion and PROs, but RCT-level evidence vs ICBG is insufficient to conclude equivalence or superiority.
Ceramic-Based Products Coverage Determination
Coverage for ceramic-based products and combinations with other graft components:
ALL of the following
Ceramic-based products (e.g., beta tricalcium phosphate (b-TCP), calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are considered unproven and not medically necessary.
This is an explicit policy-level determination added to the document.
Medical Records Documentation Requirement (Operational)
Medical records documentation may be required to assess medical necessity:
ALL of the following
Benefit coverage is determined by federal, state, or contractual requirements which may override this standard policy.
Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage.
Records must fully support medical necessity.
Required documentation includes relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.
Documentation supporting medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request.
Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral.
20930
Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure).
20931
Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure).
20939
Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
22899
Unlisted procedure, spine
No procedure or diagnosis codes listed in this partmixed
No codes listed
FDA device clearances / approvals referencedmixed
DEN200010
OptiMesh Expandable Interbody Fusion System De Novo classification (expanded indications)
K210155
Duo Expandable Interbody Fusion System 510(k) clearance (L2-L5, one or two contiguous levels, degenerative disc disease up to Grade I spondylolisthesis)
K014200
OptiMesh 510(k) clearance (maintaining position of bone graft material within a vertebral body defect)
P000058
InFUSE Bone Graft/LT-CAGE PMA (historical reference)
K172237
Bicera Resorbable Bone Substitute 501(k) premarket notification
Documentation, Prior Authorization, and Imaging Requirements
Documentation Required
Medical record documentation requirements
Medical records must fully support medical necessity for the requested osteobiologic or fusion service and may be requested for review. Documentation should be legible and maintained in the patient's medical record.
Include relevant medical history
Include physical examination findings
Include results of pertinent diagnostic tests or procedures
Records must be legible, maintained in the medical record, and made available upon request
Documentation Required
Evidence-based product selection and informed consent
When using rhBMP-2 or other biologic or synthetic substitutes, document the clinical indication, prior treatment attempts if applicable, and the clinical rationale for selecting the product instead of autograft. Obtain and document that the patient was informed of known risks, limited long-term safety data, and device-specific safety concerns (for example, life‑threatening complications reported with cervical rhBMP-2).
Clinical and Evidence Context
Autologous iliac crest bone graft (ICBG) remains the clinical gold standard for spinal fusion because it provides osteoconductive, osteoinductive, and osteogenic properties; however, its harvest is associated with donor site morbidity. Biological adjuncts such as Bone Marrow Aspirate (BMA), recombinant human bone morphogenetic protein-2 (rhBMP-2), and Demineralized Bone Matrix (DBM) may improve fusion success and enhance bone healing when used appropriately. Many newer products — including cell-based allografts, human amniotic derivatives, various ceramic-based synthetics, and bioactive glass formulations — are being investigated but generally have limited or low-quality clinical evidence to support routine use.
Evidence summarized in this policy supports that rhBMP-2 (InFUSE) has multiple randomized trials and systematic reviews showing faster and/or higher radiographic fusion rates versus autograft for certain lumbar indications, but clinical improvements in pain and function are inconsistent and long-term safety data remain limited (including a possible low cancer signal and higher complication rates for some off-label uses).
Data for ceramic-based products (for example, biphasic calcium phosphate, hydroxyapatite, tricalcium phosphate and similar synthetics) derive from multiple RCTs and intra-patient noninferiority trials that sometimes show noninferiority or equivalence to autograft in selected settings, but results are mixed and limited by small samples, heterogeneous products and procedures, intra-patient designs, and uncertain long-term outcomes; therefore, evidence does not uniformly establish clinical equivalence to ICBG.
The body of evidence for bioactive glass is limited and of very low quality: case series and small studies report promising radiographic fusion and patient-reported outcomes, but randomized controlled trial data versus ICBG are insufficient to conclude equivalence or superiority.
For expandable interbody fusion systems, the available literature is largely retrospective and of low quality; meta-analyses of mainly nonrandomized studies show some radiographic advantages (e.g., disc height, segmental lordosis) but no consistent clinical benefit versus static cages, and there are insufficient prospective randomized trials to demonstrate improved outcomes.
Key Terms and Definitions
Definitions
AllograftTransplant of tissue from one individual to another of the same species with a different genotype (allogeneic graft).
AutograftTissue grafted into a new position in the same individual's body (e.g., iliac crest bone autograft/ICBG).
Bioactive GlassSilicate glass-based materials with osteoconductive and osteoinductive properties (e.g., 45S5 formulations).
Bone Marrow AspirationRemoval of a small amount of bone marrow in liquid form for examination or grafting (BMA).
Bone Morphogenetic Proteins (BMP/rhBMP)Osteoinductive proteins that stimulate differentiation of local MSCs into osteoblasts; rhBMP produced via recombinant DNA (eg, rhBMP-2/InFUSE).
Ceramic-Based ProductsMineral salts produced at high temperatures (e.g., hydroxyapatite, tricalcium phosphate) with osteoconductive properties; includes synthetic ceramics and related substitutes.
Policy Changes and Material Updates
December 1, 2025Effective date / policy updateLatest
Policy effective date set to December 1, 2025; multiple substantive updates were made including the addition of documentation requirements, updated definitions, refreshed clinical evidence and references, and an operational coverage determination regarding ceramic-based products.
12/01/2025Revision — Coverage rationale added
Added language clarifying that Ceramic-Based Products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are considered unproven and not medically necessary.
12/01/2025
Other Policies to Review
Related policies and relationships
Discogenic Pain Treatment (for New Mexico Only)read_with
Minimally Invasive Spine Surgery Procedures (for New Mexico Only)read_with
Prolotherapy and Platelet Rich Plasma Therapies (for New Mexico Only)read_with
Skin and Soft Tissue Substitutes (for New Mexico Only)read_with
Archived prior policy version (CS009NM.B)CS009NM.B — archived
Policy Summary
PayerUnitedHealthcare
PolicySpinal Fusion and Bone Healing Enhancement Products (for New Mexico Only)
Policy CodePolicy CS009NM.C
Change TypeCoverage clarification and operational updates
Effective DateDecember 1, 2025
Next Review DateN/A
Key ActionEnsure medical records fully document medical necessity (history, physical exam, diagnostic tests) and include rationale and informed-consent details when requesting coverage for osteobiologic or fusion products.
Bioactive Glass used alone or in combination with other grafts including Bone Marrow Aspirate (BMA)
Expandable Interbody Fusion System
Expandable interbody fusion systems: Insufficient prospective randomized data; current evidence largely retrospective and low quality — outcomes (radiographic and some PRO gains) reported but clinical benefit vs static cages is unclear.
Document indication and prior treatment attempts
Document rationale for product selection over autograft
Document informed consent including limited long-term data and known device-specific risks (e.g., cervical rhBMP-2 airway/neurologic compression concerns)
Documentation Required
Imaging and follow-up documentation
If claiming improved fusion outcomes, document the radiographic modality and timing of fusion assessment used (e.g., CT at 1–2 years), and record follow-up imaging and clinical assessments; note that interpretation may be limited for ceramic materials because graft remnants can mimic bone on imaging.
Specify imaging modality (e.g., CT) and timing of fusion assessment used in follow-up
Note that many trials used CT at 12 months or later to assess fusion
Document limitation that ceramic-based products may resemble bone on imaging and affect interpretation
Prior Authorization
Prior authorization may be required for off-label biologic use
Prior authorization may be required for uses that deviate from FDA‑approved indications (for example, rhBMP-2 in cervical fusion); ensure prior authorization is obtained and document the supporting clinical rationale and risk–benefit consideration for the off‑label use.
Obtain prior authorization for off‑label biologic/synthetic use (e.g., cervical rhBMP-2)
Provide clinical rationale and documentation of risk–benefit assessment with the authorization request
Documentation Required
Maintain complete medical record documentation
Ensure the patient's medical record contains complete, legible documentation that fully supports medical necessity for requested osteobiologic or fusion services; records may be requested during utilization review and do not guarantee coverage.
Include relevant history, physical exam, and results of pertinent diagnostic tests or procedures
Maintain documentation in the medical record and make it available upon request
Taken together, the strongest and most consistent high-quality evidence in this policy supports specific labeled uses of rhBMP-2 for selected single-level lumbar interbody fusions, whereas ceramics, bioactive glass, cell-based and many other newer osteobiologic technologies remain supported by limited, heterogeneous, or low-quality evidence and are considered unproven for broad use.
Demineralized Bone Matrix (DBM)An allograft produced by dissolving the mineralized portion of bone leaving collagen matrix and growth factors; requires a carrier for scaffold (DBM).
InFUSE Bone GraftAn absorbable collagen sponge coated with rhBMP-2 approved for certain lumbar spine indications (L2–S1).
MASTERGRAFTPosterolateral revision device system used with InFUSE in FDA‑approved posterolateral pseudoarthrosis indications.
ICBGIliac crest bone graft (autograft taken from the patient's iliac crest), the traditional gold standard for many spine fusions.
rhBMP-2Recombinant human bone morphogenetic protein-2, a biologic osteoinductive agent used to promote spinal fusion (component of InFUSE).
Ceramic-based products (synthetic)Synthetic, biologically inert or bioactive materials (e.g., biphasic calcium phosphate, hydroxyapatite, tricalcium phosphate, SiCaP) used as bone graft substitutes.
Bioactive glassSilica-based synthetic materials claimed to promote bone bonding and osteoconductivity (e.g., 45S5 formulations).
Expandable interbody fusion systemsIntervertebral cages or spacers that expand in situ to restore disc height and lordosis (expandable interbody fusion systems).
OsseointegrationStable anchorage of an implant achieved by direct bone-to-implant contact (newly added definition).
OsteoconductionBone grows on the surface; a process describing scaffold-guided bone formation (newly added definition).
OsteoinductionProcess by which osteogenesis is induced via recruitment and stimulation of immature cells to become preosteoblasts (newly added definition).
Revision — Medical records documentation
Added and expanded medical records documentation requirements noting that benefit coverage is subject to federal/state/contractual requirements and that documentation (history, physical exam, diagnostic test results) may be requested and must be legible and maintained in the medical record.
12/01/2025Revision — Definitions updated/added
Added definitions for Osseointegration, Osteoconduction, and Osteoinduction and updated definitions for Allograft, Autograft, and Bone Marrow Aspiration to improve policy clarity.
12/01/2025Revision — Administrative / supporting information
Removed certain related policy reference links, archived prior policy version CS009NM.B, and updated the Clinical Evidence and References sections to reflect current information.